Evidence map›Paper›PMID 39397652›Full record

ArticleStereotactic and functional neurosurgery2024

Combination of or Transition between Deep Brain Stimulation and Responsive Neurostimulation for the Treatment of Drug-Resistant Epilepsy.

Jimmy C Yang, Henry Skelton, Faical Isbaine, Katie L Bullinger, Abdulrahman Alwaki, Brian T Cabaniss, Jon T Willie, Robert E Gross

Abstract read
In one paragraph

Article in Stereotactic and functional neurosurgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jimmy C YangDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio, USA, jimmy.c.yang@gmail.com.
Henry SkeltonDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Faical IsbaineDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Katie L BullingerDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Abdulrahman AlwakiDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Brian T CabanissDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Jon T WillieDepartment of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Robert E GrossDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA.

Funding

Neurosurgeon Research Career Development Program (NRCDP)K12NS129164 · NINDS · WASHINGTON UNIVERSITY · PI Sepideh Amin-Hanjani, Emad N Eskandar · 2023 to 2026
$6.7M
NINDS NIH HHS K12 NS129164
6 · The paper itself

Abstract

introductionNeuromodulation is an important treatment modality for patients with drug-resistant epilepsy who are not candidates for resective or ablative procedures. However, randomized controlled trials and real-world studies reveal that a subset of patients will experience minimal reduction or even an increase in seizure frequency after neuromodulation. We describe our experience with patients who undergo a second intracranial neuromodulation procedure after unsatisfactory initial response to intracranial neuromodulation.

methodsWe performed a retrospective chart review to identify all patients who had undergone deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) or responsive neurostimulation (RNS), followed by additional intracranial neuromodulatory procedures, with at least 12 months of follow-up. Demographic and clinical data, including seizure frequencies, were collected.

resultsAll patients had temporal lobe epilepsy. Six patients were treated with concurrent ANT DBS and temporal lobe RNS, and 3 patients transitioned between neuromodulation systems. Of the patients treated concurrently with ANT DBS and temporal lobe RNS, 5 of the 6 patients experienced additional reduction in seizure frequency after adding a second neuromodulation system. Of the patients who switched between neuromodulation modalities, all patients experienced further reduction in seizure frequency.

conclusionsFor patients who do not experience adequate benefit from initial therapy with ANT DBS or temporal lobe RNS, the addition of a neuromodulation system or switching to a different form of neuromodulation may allow for additional reduction in seizure frequency. Larger studies will need to be performed to understand whether the use of multiple systems concurrently leads to improved clinical results in patients who are initially treatment resistant to neuromodulation.

Indexed as

Deep Brain StimulationDrug Resistant EpilepsyAdultAnterior Thalamic NucleiCombined Modality TherapyEpilepsy, Temporal LobeFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultDeep brain stimulationEpilepsyNeuromodulationResponsive neurostimulation

Identifiers

PMID39397652
PMCPMC11694315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.